While the tech industry obsesses over sleep scores and heart rate variability, 1.3 billion women globally enter menopause with little more than a vague symptom diary. Amissa is betting that your Apple Watch knows more about your perimenopause journey than your doctor does—and they're building the OS to prove it.

"Amissa isn't tracking your fitness—it's tracking your biology's rebellion against time."

The founder, Jon Corkey, is playing a long game. Amissa's social presence is minimal—just a Facebook page, LinkedIn company profile, and Instagram with barely any traction. This isn't a DTC brand chasing virality. It's a clinical tool quietly embedding itself into menopause care workflows. The lack of funding data and Trustpilot reviews suggests they're either pre-Series A or deliberately staying under the radar while validating with pilot clinicians.

• Biometric-symptom correlation engine (Apple Watch → clinical insight)
• B2B2C model: clinicians as prescribers, patients as data generators
• Built on modern stack: Next.js, Vercel, Tailwind, PostHog
• Top organic query: 'perimenopause muscle aches' (390 monthly)
• 9-person team generating $0.7M revenue with zero marketing spend